Despite slow start to 2015 clinical activity, rates predicted to go up

June 3, 2015 Guest Contributor

Surani FernandoGuest post by Surani Fernando, Acting Editor, EMEA, BioPharm Insight

BioPharm Insight‘s Clinical Activity Report (in collaboration with BioPharm Clinical) delves into the 5020 studies initiated in 1Q15 globally. While initiations saw a 30% drop, this may just indicate a slow start to the year and rates may pick up during the course of 2015. Phase II initiations continue to be the most abundant in 1Q15 (similar to 1Q14), while Phase Ib studies make a notable increase—a potential trend in companies targeting more severe diseases. Cancer continues to lead the therapeutic list of ongoing trials, while leukemia trials see the largest increase from 2014. A 44% decrease in type 2 diabetes studies could indicate industry’s acceptance of the market saturation in this area. While it’s not surprising that the US and Europe continue to dominate as regional hubs of trial activity, Egypt saw a surprise entry into the top 20, potentially offering more attractive cost efficiencies than the more popular regions.

Please click here for the 1Q15 Clinical Activity report. To request a free trial with BPI, please click here.

Read more...

Previous Article
Aisling Capital’s Dennis Purcell on Boston, serial entrepreneurs, and leveraging the life science ecosystem
Aisling Capital’s Dennis Purcell on Boston, serial entrepreneurs, and leveraging the life science ecosystem

No other industry relies on cross-pollinating collaborations that span the ecosystem like biotech. From sta...

Next Article
Put the life science ecosystem to work for you in Boston
Put the life science ecosystem to work for you in Boston

ENGAGE and DE-RISK. These two terms describe the enormous task of drug development, which is best achieved ...